This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Citrix Systems, Inc.: A Fight Worth Fighting?
Loutskina, Elena; Shah, JigarCase DARDEN-F-2049-EFinanceIn December 2021, Valiant Capital Partners (VCP) is in the middle of bidding for Citrix Systems, Inc. (Citrix), to take the company private via a leveraged buyout (LBO). The auction of the renowned desktop-as-a-service (DaaS) company had attracted a number of bidders. VCP's initial bid of $15 billion ($92 per share) had allowed the fund to move to the final bidding round. Now with broader access to the company and its management, VCP has to revis...Starting at €8.20
-
Xanadu Farms: Weathering the Uncertainty
Tiffany BayleyExercise IVEY-W33716-EDecision Analysis, Service and Operations ManagementIn March 2023, two strawberry producers in Ontario, Canada had to decide how many acres to plant with each of four strawberry varieties at Xanadu Farms. They had committed to providing 275,000 pounds of berries to a local independent grocery chain and also required some of their berry crop to make strawberry preserves. Complicating this decision was the impact that weather had on the yield of each type of berry. If the weather reduced the yield, ...Starting at €8.20
-
St. Gianna Healthcare: Service Management - Teaching Note
Joshin John; Neetha J. EappenTeaching Note IVEY-W33858-EDecision Analysis, Service and Operations ManagementTeaching note for product W33857.Starting at €0.00
-
Freeze (B): Handling A Whistle-Blowing Report
Paulina Arroyo; Vicky Poirier; Myriam Levesque; Nadia SmailiCase IVEY-W33372-EAccounting and Control, FinanceThis is the supplemental B-case for product W33370.Starting at €5.74
-
Freeze (A–B): Handling a Whistle-blowing Report - Teaching Note
Paulina Arroyo; Vicky Poirier; Myriam Levesque; Nadia SmailiTeaching Note IVEY-W33371-EAccounting and Control, FinanceTeaching note for products W33370 and W33372.Starting at €0.00
-
Forecasting Climate Risks: Aviva's Climate Calculus
Egan, Mark; Tufano, PeterCase HBS-224025-EFinanceIn late 2021, Ben Carr, Director of Analytics and Capital Modeling at Aviva Plc (Aviva)-a leading insurer with core operations in the UK, Ireland and Canada,-was preparing for an upcoming presentation before the company's board which included its CEO, Amanda Blanc, featuring the results of Aviva's performance in the Climate Biennial Exploratory Scenario (CBES) exercise mandated by the Bank of England. The CBES required all major banks and insurer...Starting at €8.20
-
Apple Inc.: The Second Green Bond - Teaching note
Lipson, Marc L.Teaching Note DARDEN-F-2022TN-EFinanceLisa Jackson, vice president of Environment, Policy and Social Initiatives at Apple Inc. (Apple) and, previously, the first African American administrator of the Environmental Protection Agency, was preparing for questions that might arise in relation to Apple's upcoming 10-year $1 billion green bond issue, Apple's second such offering. The case explores the economics of bond pricing in general, and green bonds in particular, by describing the re...Starting at €0.00
-
Assessing Private Equity Performance
Chaplinsky, Susan; Loutskina, ElenaTechnical Note DARDEN-F-1895-EFinanceAssessing the performance of private equity (PE) and venture capital (VC) investment vehicles is a challenging task. It starts with the fact that the assets are privately held and illiquid. By contrast, PE valuations are determined in a vast open market populated largely by disinterested investors acting on publicly available information. As PE and VC have grown as asset classes, investors have pushed for greater disclosure and more standardizati...Starting at €8.20
-
The End of Credit Suisse - Teaching note
Allayannis, George (Yiorgos)Teaching Note DARDEN-F-2064TN-EFinanceStarting at €0.00
-
Venture Capital in Biotechnology
Matherne, G. (Paul); Herpfer, Christoph; Dow, EthanTechnical Note DARDEN-OM-1796-EService and Operations ManagementPharmaceutical companies have historically relied on their ability to research, develop, manufacture, and sell drug products. Developing a successful drug is a complex and lengthy process, with no guarantee of success, and the total cost of approving a new drug is estimated at $2.5 billion, and rising. This technical note offers an overview of changes in the biotechnology industry related to drug development, focusing on M&A, the milestone model,...Starting at €8.20